Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients.
adjuvant/salvage radiotherapy
pattern of recurrence
pelvic radiotherapy
prostate bed radiotherapy
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
09
2021
accepted:
16
11
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
epublish
Résumé
Although salvage and adjuvant radiotherapy (RT) are effective in prostate cancer (PC) patients, 30%-40% of men will have disease progression. The objective was to describe the pattern of recurrence in PC patients with biochemical failure (BF) following postoperative RT. We retrospectively analyzed 935 PC patients treated from 2009 to 2019 with adjuvant or salvage RT at the Institut de Cancérologie de l'Ouest. Of these, 205 (22%) developed BF of whom 166 underwent imaging. Patients with identified radiologic failure prior any specific treatment were included to determine the site of relapse categorized as local (L)-only, locoregional (LR), or metastatic (M) recurrence. Main disease characteristics and RT fields were examined in relation to sites of recurrence. One hundred forty-one patients were identified with 244 sites of failure on imaging. Of these, 108 patients had received RT to the PB alone and 33 RT to the PB and pelvic lymph nodes (PB+PLN). Androgen-deprivation therapy was used concomitantly in 50 patients (35%). The median PSA at imaging was 1.6 ng/ml (range, 0-86.7). In all, 74 patients (52%) had M disease (44% in the PB group and 79% in the PB+PLN group), 61 (43%) had LR failure (52% in the PB alone group and 15% in the PB+PLN group), and six (4%) had L-only failure, at a median of 26.7 months (range, 5-110.3) from RT. Metastases were in extra-pelvic LN (37 (15%)), bones (66 (27%)), and visceral organs (eight (3%)). Fifty-three (48%) of the pelvic LN failures in the PB group would have been encompassed by standard PLN RT volume. We found that most patients evaluated for BF after postoperative RT recurred outside the RT field. Isolated pelvic nodal failure was rare in those receiving RT to the PB+PLN but accounted for half of failures in those receiving PB alone RT. Imaging directed salvage treatment could be helpful to personalize radiation therapy plan.
Identifiants
pubmed: 35070993
doi: 10.3389/fonc.2021.787347
pmc: PMC8766670
doi:
Types de publication
Journal Article
Langues
eng
Pagination
787347Informations de copyright
Copyright © 2022 Gonzalez-Moya, Supiot, Seegers, Lizée, Legouté, Perennec and Calais.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8
pubmed: 19394158
JAMA Oncol. 2020 May 1;6(5):735-743
pubmed: 32215583
J Clin Oncol. 2007 May 20;25(15):2035-41
pubmed: 17513807
Eur Urol Oncol. 2019 Feb;2(1):47-76
pubmed: 30929846
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
Adv Radiat Oncol. 2020 Aug 31;5(6):1126-1140
pubmed: 33305073
J Clin Oncol. 2016 Oct 20;34(30):3648-3654
pubmed: 27528718
Clin Oncol (R Coll Radiol). 2010 Feb;22(1):46-55
pubmed: 19948393
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1243-1253
pubmed: 33186618
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
JAMA. 2005 Jul 27;294(4):433-9
pubmed: 16046649
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
Eur Urol. 2016 Jul;70(1):161-175
pubmed: 26850970
Eur Urol. 2021 Sep;80(3):306-315
pubmed: 34140144
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7
pubmed: 18947938
J Natl Cancer Inst. 2006 May 17;98(10):715-7
pubmed: 16705126
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503149
Lancet Oncol. 2018 Nov;19(11):1504-1515
pubmed: 30316827
Eur Urol. 2017 Mar;71(3):340-348
pubmed: 27597240
BJU Int. 2016 May;117(5):732-9
pubmed: 26683282
J Clin Oncol. 2016 Nov 10;34(32):3864-3871
pubmed: 27480153
Radiat Oncol. 2021 Feb 10;16(1):32
pubmed: 33568190
J Clin Oncol. 2007 Dec 1;25(34):5366-73
pubmed: 18048817
Radiother Oncol. 2019 Dec;141:174-180
pubmed: 31563410
Radiother Oncol. 2018 Feb;126(2):244-248
pubmed: 29132644
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535
pubmed: 28126302
Cancer Radiother. 2019 Jun;23(3):194-200
pubmed: 31088725
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
BJU Int. 2017 Sep;120(3):351-357
pubmed: 28139024
J Nucl Med. 2018 Feb;59(2):230-237
pubmed: 29123013
Semin Urol Oncol. 1999 Aug;17(3):130-4
pubmed: 10462315
Eur Urol. 2021 Oct;80(4):405-414
pubmed: 34247896